FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1156-1162 October 19, 2000 Number 16 Next

	Full Text PDF Editorial by Falk, R. J. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The combination of cyclophosphamide and prednisolone is effective for the treatment of severe lupus nephritis but has serious adverse effects. Whether mycophenolate mofetil can be substituted for cyclophosphamide is not known.

Methods In 42 patients with diffuse proliferative lupus nephritis we compared the efficacy and side effects of a regimen of prednisolone and mycophenolate mofetil given for 12 months with those of a regimen of prednisolone and cyclophosphamide given for 6 months, followed by prednisolone and azathioprine for 6 months. Complete remission was defined as a value for urinary protein excretion that was less than 0.3 g per 24 hours, with normal urinary sediment, a normal serum albumin concentration, and values for serum creatinine and creatinine clearance that were no more than 15 percent above the base-line values. Partial remission was defined as a value for urinary protein excretion that was between 0.3 and 2.9 g per 24 hours, with a serum albumin concentration of at least 3.0 g per deciliter.

Results Eighty-one percent of the 21 patients treated with mycophenolate mofetil and prednisolone (group 1) had a complete remission, and 14 percent had a partial remission, as compared with 76 percent and 14 percent, respectively, of the 21 patients treated with cyclophosphamide and prednisolone followed by azathioprine and prednisolone (group 2). The improvements in the degree of proteinuria and the serum albumin and creatinine concentrations were similar in the two groups. One patient in each group discontinued treatment because of side effects. Infections were noted in 19 percent of the patients in group 1 and in 33 percent of those in group 2 (P=0.29). Other adverse effects occurred only in group 2; they included amenorrhea (in 23 percent of the patients), hair loss (19 percent), leukopenia (10 percent), and death (10 percent). The rates of relapse were 15 percent and 11 percent, respectively.

Conclusions For the treatment of diffuse proliferative lupus nephritis, the combination of mycophenolate mofetil and prednisolone is as effective as a regimen of cyclophosphamide and prednisolone followed by azathioprine and prednisolone.

Source Information

From the Nephrology Division, Department of Medicine, University of Hong Kong and Queen Mary Hospital, Hong Kong, China.

Address reprint requests to Dr. T.M. Chan at the Nephrology Division, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam Rd., Hong Kong, China, or at dtmchan{at}hku.hk.

Full Text of this Article

This article has been cited by other articles:

• Bao, H., Liu, Z.-H., Xie, H.-L., Hu, W.-X., Zhang, H.-T., Li, L.-S. (2008). Successful Treatment of Class V+IV Lupus Nephritis with Multitarget Therapy. J. Am. Soc. Nephrol. 19: 2001-2010 [Abstract] [Full Text]  
• Lv, J., Zhang, H., Cui, Z., Su, T., Zhang, Y., Wang, H. (2008). Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. Nephrol Dial Transplant 23: 2868-2872 [Abstract] [Full Text]  
• Traitanon, O, Avihingsanon, Y, Kittikovit, V, Townamchai, N, Kanjanabuch, T, Praditpornsilpa, K, Wongchinasri, J, Tungsanga, K, Eiam-Ong, S (2008). Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study. Lupus 17: 744-751 [Abstract]  
• Chan, T. (2008). Mycophenolate mofetil in the treatment of lupus nephritis - 7 years on. Lupus 17: 617-621  
• F, L., Y, T., X, P., L, W., H, W., Z, S., H, Z., Z, H. (2008). A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus 17: 622-629 [Abstract]  
• Neumann, I., Fuhrmann, H., Fang, I-F., Jaeger, A., Bayer, P., Kovarik, J. (2008). Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrol Dial Transplant 0: gfn360v1-gfn360 [Abstract] [Full Text]  
• Houssiau, F., Ginzler, E. (2008). Current treatment of lupus nephritis. Lupus 17: 426-430 [Abstract]  
• Bertsias, G, Ioannidis, J P A, Boletis, J, Bombardieri, S, Cervera, R, Dostal, C, Font, J, Gilboe, I M, Houssiau, F, Huizinga, T, Isenberg, D, Kallenberg, C G M, Khamashta, M, Piette, J C, Schneider, M, Smolen, J, Sturfelt, G, Tincani, A, van Vollenhoven, R, Gordon, C, Boumpas, D T (2008). EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67: 195-205 [Abstract] [Full Text]  
• Kasitanon, N., Petri, M., Haas, M., Magder, L.S., Fine, D.M. (2008). Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases. Lupus 17: 40-45 [Abstract]  
• Chen, Y. E., Korbet, S. M., Katz, R. S., Schwartz, M. M., Lewis, E. J., for the Collaborative Study Group, (2008). Value of a Complete or Partial Remission in Severe Lupus Nephritis. CJASN 3: 46-53 [Abstract] [Full Text]  
• Sinclair, A., Appel, G., Dooley, M.A., Ginzler, E., Isenberg, D., Jayne, D., Wofsy, D., Solomons, N. (2007). Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 16: 972-980 [Abstract]  
• Petri, M. (2007). Disease activity assessment in SLE: do we have the right instruments?. Ann Rheum Dis 66: iii61-iii64 [Abstract] [Full Text]  
• Wang, J., Hu, W., Xie, H., Zhang, H., Chen, H., Zeng, C., Liu, Z., Li, L. (2007). Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 16: 707-712 [Abstract]  
• de Castro, W.P., Morales, J.V., Wagner, M.B., Graudenz, M., Edelweiss, M.I., Goncalves, L.F. (2007). Hypertension and Afro-descendant ethnicity: a bad interaction for lupus nephritis treated with cyclophosphamide?. Lupus 16: 724-730 [Abstract]  
• Walsh, M., James, M., Jayne, D., Tonelli, M., Manns, B. J., Hemmelgarn, B. R. (2007). Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis. CJASN 2: 968-975 [Abstract] [Full Text]  
• Contreras, G., Sosnov, J. (2007). Role of Mycophenolate Mofetil in the Treatment of Lupus Nephritis. CJASN 2: 879-882 [Full Text]  
• Ranchin, B., Fargue, S. (2007). Review: New treatment strategies for proliferative lupus nephritis: keep children in mind!. Lupus 16: 684-691 [Abstract]  
• Zhu, B., Chen, N., Lin, Y., Ren, H., Zhang, W., Wang, W., Pan, X., Yu, H. (2007). Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 22: 1933-1942 [Abstract] [Full Text]  
• Parker, B., Bruce, I. (2007). High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus 16: 387-393 [Abstract]  
• Stassen, P. M, Cohen Tervaert, J. W., Stegeman, C. A (2007). Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 66: 798-802 [Abstract] [Full Text]  
• Zandi, M. S, Coles, A. J (2007). Notes on the kidney and its diseases for the neurologist. J. Neurol. Neurosurg. Psychiatry 78: 444-449 [Abstract] [Full Text]  
• Hunt, B.J., Tueger, S., Pattison, J., Cavenagh, J., D'Cruz, D.P. (2007). Microangiopathic haemolytic anaemia secondary to lupus nephritis: an important differential diagnosis of thrombotic thrombocytopenic purpura. Lupus 16: 358-362 [Abstract]  
• Stassen, P. M., Kallenberg, C. G. M., Stegeman, C. A. (2007). Use of mycophenolic acid in non-transplant renal diseases. Nephrol Dial Transplant 22: 1013-1019 [Full Text]  
• Houssiau, F (2007). Thirty years of cyclophosphamide: assessing the evidence. Lupus 16: 212-216 [Abstract]  
• Haubitz, M (2007). Exploring new territory: the move towards individualised treatment. Lupus 16: 227-231 [Abstract]  
• Nihtyanova, S. I., Brough, G. M., Black, C. M., Denton, C. P. (2007). Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) 46: 442-445 [Abstract] [Full Text]  
• Alperovich, G, Rama, I, Lloberas, N, Franquesa, M, Poveda, R, Goma, M, Herrero-Fresneda, I, Cruzado, J M, Bolanos, N, Carrera, M, Grinyo, J M, Torras, J (2007). New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus 16: 18-24 [Abstract]  
• Tse, K C, Lam, M F, Tang, S C., Tang, C S., Chan, T M (2007). A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus 16: 46-51 [Abstract]  
• Doria, A, Iaccarino, L, Arienti, S, Rampudda, M E, Canova, M G, Rondinone, R, Todesco, S (2006). Mycophenolate mofetil and systemic lupus erythematosus. Lupus 15: 44-54 [Abstract]  
• Sinclair, A, Baildon, R (2006). Mycophenolate mofetil: an overview. Lupus 15: 70-77  
• Moroni, G., Doria, A., Mosca, M., Alberighi, O. D. C., Ferraccioli, G., Todesco, S., Manno, C., Altieri, P., Ferrara, R., Greco, S., Ponticelli, C. (2006). A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years. CJASN 1: 925-932 [Abstract] [Full Text]  
• Swigris, J. J., Olson, A. L., Fischer, A., Lynch, D. A., Cosgrove, G. P., Frankel, S. K., Meehan, R. T., Brown, K. K. (2006). Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.. Chest 130: 30-36 [Abstract] [Full Text]  
• Bihl, G. R., Petri, M., Fine, D. M. (2006). Kidney biopsy in lupus nephritis: look before you leap. Nephrol Dial Transplant 21: 1749-1752 [Full Text]  
• Ponticelli, C. (2006). New Therapies for Lupus Nephritis. CJASN 1: 863-868 [Full Text]  
• Tse, K C, Tang, C S., Lio, W I, Lam, M F, Chan, T M (2006). Quality of life comparison between corticosteroidand-mycofenolate mofetil and corticosteroidand-oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus 15: 371-379 [Abstract]  
• Dooley, M A (2006). Mycophenylate mofetil: what role in the treatment of lupus?. Lupus 15: 179-182 [Abstract]  
• Burt, R. K., Traynor, A., Statkute, L., Barr, W. G., Rosa, R., Schroeder, J., Verda, L., Krosnjar, N., Quigley, K., Yaung, K., Villa, BS, M., Takahashi, M., Jovanovic, B., Oyama, Y. (2006). Nonmyeloablative Hematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus. JAMA 295: 527-535 [Abstract] [Full Text]  
• Tse, K C, Li, F K, Tang, S, Tang, C S-O, Lai, K N, Chan, T M (2005). Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus 14: 947-952 [Abstract]  
• Joy, M. S., Hogan, S. L., Jennette, J. C., Falk, R. J., Nachman, P. H. (2005). A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 20: 2725-2732 [Abstract] [Full Text]  
• Ginzler, E. M., Dooley, M. A., Aranow, C., Kim, M. Y., Buyon, J., Merrill, J. T., Petri, M., Gilkeson, G. S., Wallace, D. J., Weisman, M. H., Appel, G. B. (2005). Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis.. NEJM 353: 2219-2228 [Abstract] [Full Text]  
• McCune, W. J. (2005). Mycophenolate Mofetil for Lupus Nephritis.. NEJM 353: 2282-2284 [Full Text]  
• Dasgupta, N, Gelber, A C, Racke, F, Fine, D M (2005). Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis. Lupus 14: 910-913 [Abstract]  
• Mak, A, Mok, C C (2005). Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus 14: 856-858 [Abstract]  
• Karim, M. Y., Pisoni, C. N., Ferro, L., Tungekar, M. F., Abbs, I. C., D'Cruz, D. P., Khamashta, M. A., Hughes, G. R. V. (2005). Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 44: 1317-1321 [Abstract] [Full Text]  
• Guo, H, Leung, J C., Chan, L Y., Lui, S L, Tsang, A W., Lai, K N (2005). Modulation of intra-pulmonary TGF-b expression by mycophenolate mofetil in lupus prone MRL/lpr mice. Lupus 14: 583-592 [Abstract]  
• Rahman, A., Bowman, S. J., Giles, I. P., Ioannou, Y., Isenberg, D. A. (2005). Annus mirabilis--a guide to the 6th European Lupus Meeting, 3-5 March 2005. Rheumatology (Oxford) 44: 962-964 [Full Text]  
• Thomas, M, Blennerhassett, J, Walker, R (2005). Relapse with transformation of lupus nephritis in a transplant kidney. Lupus 14: 554-556 [Abstract]  
• Stummvoll, G H, Aringer, M, Smolen, J S, Schmaldienst, S, Jimenez-Boj, E, Horl, W H, Graninger, W B, Derfler, K (2005). IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis 64: 1015-1021 [Abstract] [Full Text]  
• Fine, D. M. (2005). Pharmacological Therapy of Lupus Nephritis. JAMA 293: 3053-3060 [Abstract] [Full Text]  
• Chan, T M, Tse, K C, Tang, C S., Lai, K N, Li, F K (2005). Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 14: 265-272 [Abstract]  
• Chan, T.-M., Tse, K.-C., Tang, C. S.-O., Mok, M.-Y., Li, F.-K., for the Hong Kong Nephrology Study Group, (2005). Long-Term Study of Mycophenolate Mofetil as Continuous Induction and Maintenance Treatment for Diffuse Proliferative Lupus Nephritis. J. Am. Soc. Nephrol. 16: 1076-1084 [Abstract] [Full Text]  
• Vasoo, S, Hughes, G R. (2005). Theory, targets and therapy in systemic lupus erythematosus. Lupus 14: 181-188 [Abstract]  
• Pisoni, C N, Karim, Y, Cuadrado, M J (2005). Mycophenolate mofetil and systemic lupus erythematosus: an overview. Lupus 14: s9-s11 [Abstract]  
• Chan, T M (2005). Lupus nephritis: induction therapy. Lupus 14: s27-s32 [Abstract]  
• Contreras, G, Tozman, E, Nahar, N., Metz, D. (2005). Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 14: s33-s38 [Abstract]  
• Ramos-Casals, M, Font, J (2005). Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 14: s64-s72 [Abstract]  
• Gorman, C., Bhatia, A., Rahman, A. (2005). This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis. Rheumatology (Oxford) 44: 398-401 [Full Text]  
• D'Cruz, D. P, Hughes, G. R V (2005). The treatment of lupus nephritis. BMJ 330: 377-378 [Full Text]  
• Chung, L, Berry, G J, Chakravarty, E F (2005). Giant cell myocarditis: a rare cardiovascular manifestation in a patient with systemic lupus erythematosus. Lupus 14: 166-169 [Abstract]  
• Balow, J E (2005). Clinical presentation and monitoring of lupus nephritis. Lupus 14: 25-30 [Abstract]  
• Mok, C C (2005). Prognostic factors in lupus nephritis. Lupus 14: 39-44 [Abstract]  
• Sidiropoulos, P I, Kritikos, H D, Boumpas, D T (2005). Lupus nephritis flares. Lupus 14: 49-52 [Abstract]  
• Houssiau, F A (2005). Cyclophosphamide in lupus nephritis. Lupus 14: 53-58 [Abstract]  
• Ginzler, E M, Aranow, C (2005). Mycophenolate mofetil in lupus nephritis. Lupus 14: 59-64 [Abstract]  
• Tahir, H, Isenberg, D A (2005). Novel therapies in lupus nephritis. Lupus 14: 77-82 [Abstract]  
• Pisoni, C., Karim, Y., Cuadrado, M. (2005). Mycophenolate mofetil and systemic lupus erythematosus: an overview. Lupus 14: s9-s11 [Abstract]  
• Chan, T. (2005). Lupus nephritis: induction therapy. Lupus 14: s27-s32 [Abstract]  
• Contreras, G., Tozman, E., Nahar, N., Metz, D. (2005). Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 14: s33-s38 [Abstract]  
• Ramos-Casals, M., Font, J. (2005). Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 14: s64-s72 [Abstract]  
• Raptopoulou, A., Sidiropoulos, P., Boumpas, D. T (2004). Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus. Lupus 13: 887-890  
• Jones, G., Juszczak, M., Kingdon, E., Harber, M., Sweny, P., Burns, A. (2004). Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant 19: 3160-3164 [Abstract] [Full Text]  
• Houssiau, F. A. (2004). Management of Lupus Nephritis: An Update. J. Am. Soc. Nephrol. 15: 2694-2704 [Full Text]  
• Kamal, M. A., Jusko, W. J. (2004). Interactions of Prednisolone and Other Immunosuppressants Used in Dual Treatment of Systemic Lupus Erythematosus in Lymphocyte Proliferation Assays. J Clin Pharmacol 44: 1034-1045 [Abstract] [Full Text]  
• Ahmadi-Simab, K, Lamprecht, P, Gross, W L (2004). Progression of lupus nephritis during treatment with mycophenolate mofetil. Ann Rheum Dis 63: 1179-1180 [Full Text]  
• Vasoo, S (2004). First international meeting on mycophenolate mofetil: an advance in the treatment of lupus 27 April 2004, St Thomas' Hospital, London, UK. Lupus 13: 543-545  
• Yee, C.-S., Gordon, C., Gelber, A. C., Christopher-Stine, L., Fine, D. M., Farhey, Y., Hess, E., Contreras, G., Lenz, O., Roth, D. (2004). Sequential Therapies for Proliferative Lupus Nephritis. NEJM 350: 2518-2520 [Full Text]  
• Petri, M (2004). Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 13: 366-371 [Abstract]  
• Sidiropoulos, P I, Boumpas, D T (2004). Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13: 391-397 [Abstract]  
• Schiffenbauer, J, Simon, L S (2004). Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do?. Lupus 13: 398-405 [Abstract]  
• Somers, M. J., Daouk, G. H., McCluskey, R. T. (2004). Case 11-2004 - A Boy with Rash, Edema, and Hypertension. NEJM 350: 1550-1559 [Full Text]  
• Contreras, G., Pardo, V., Leclercq, B., Lenz, O., Tozman, E., O'Nan, P., Roth, D. (2004). Sequential Therapies for Proliferative Lupus Nephritis. NEJM 350: 971-980 [Abstract] [Full Text]  
• Balow, J. E., Austin, H. A. III (2004). Maintenance Therapy for Lupus Nephritis -- Something Old, Something New. NEJM 350: 1044-1046 [Full Text]  
• Kapitsinou, P. P., Boletis, J. N., Skopouli, F. N., Boki, K. A., Moutsopoulos, H. M. (2004). Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford) 43: 377-380 [Abstract] [Full Text]  
• Karim, Y, D'Cruz, D P (2004). The NIH pulse cyclophosphamide regime: the end of an era?. Lupus 13: 1-3  
• Hahn, B. H. (2003). Systemic Lupus Erythematosus and Accelerated Atherosclerosis. NEJM 349: 2379-2380 [Full Text]  
• Dubus, I., L'Azou, B., Gordien, M., Delmas, Y., Labouyrie, J.-P., Bonnet, J., Combe, C. (2003). Cytoskeletal Reorganization by Mycophenolic Acid Alters Mesangial Cell Migration and Contractility. Hypertension 42: 956-961 [Abstract] [Full Text]  
• El Hachmi, M, Jadoul, M, Lefebvre, C, Depresseux, G, Houssiau, F A (2003). Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 12: 692-696 [Abstract]  
• Mok, C C, Lau, C S (2003). Lupus in Hong Kong Chinese. Lupus 12: 717-722 [Abstract]  
• Mavragani, C P, Moutsopoulos, H M (2003). Lupus nephritis: current issues. Ann Rheum Dis 62: 795-798 [Full Text]  
• Mok, C C, Wong, R W S, Lai, K N (2003). Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis 62: 799-804 [Abstract] [Full Text]  
• Polenakovic, M., Grcevska, L., Dzikova, S. (2003). Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy. Nephrol Dial Transplant 18: 1233-1234 [Full Text]  
• Bijl, M, Horst, G, Bootsma, H, Limburg, P C, Kallenberg, C G M (2003). Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 62: 534-539 [Abstract] [Full Text]  
• Vinen, C S, Oliveira, D B G (2003). Acute glomerulonephritis. Postgrad. Med. J. 79: 206-213 [Abstract] [Full Text]  
• Neumann, I., Haidinger, M., Jager, H., Grutzmacher, H., Griesmacher, A., Muller, M. M., Bayer, P. M., Thomas Meisl, F. (2003). Pharmacokinetics of Mycophenolate Mofetil in Patients with Autoimmune Diseases Compared Renal Transplant Recipients. J. Am. Soc. Nephrol. 14: 721-727 [Abstract] [Full Text]  
• Zatz, R., Noronha, I. L., Fujihara, C. K. (2002). Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies. Am. J. Physiol. Renal Physiol. 283: F1167-F1175 [Abstract] [Full Text]